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ABSTRACT 22 
A resazurin chromogenic agar (RCA) along with combined disc method has been 23 
developed as a promising method for rapid screening of extended-spectrum-β-lactamase 24 
(ESBL), AmpC β-lactamase, and co-production of ESBL and AmpC. Cefpodoxime 25 
(CPD) discs supplemented with and without clavulanic acid (CA), cloxacillin (CX), or 26 
CA+CX were evaluated against 86-molecularly confirmed β-lactamase-producing 27 
Enterobacteriaceae, including 15 ESBLs, 32 AmpCs, 9 co-producers of ESBL and 28 
AmpC, and 30 carbapenemase producers. The CA and CX synergy test successfully 29 
detected all ESBL producers (100% sensitivity and 98.6% specificity) and all AmpC 30 
producers (100% sensitivity and 96.36% specificity). This assay also exhibited a good 31 
performance in the screening for the co-existence of ESBL and AmpC (88.89% 32 
sensitivity and 100% specificity). The RCA assay is a simple and inexpensive method 33 
that allows observation of results within 7 h. It can be applicable in any microbiological 34 
laboratory, especially in the endemic areas of ESBL, AmpC, or co-β-lactamase-35 
producing Enterobacteriaceae. 36 
 37 
KEYWORDS: Resazurin chromogenic agar, cefpodoxime combined disc, phenotypic 38 
test, β-lactamases, Enterobacteriaceae.  39 
 40 
 41 
 42 
 43 
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1. INTRODUCTION 44 
An increasing number of antibiotic-resistant opportunistic pathogens have globally been 45 
documented in recent years resulting in decreasing effective antibiotic availability. Not 46 
surprisingly, these problems have created a treatment challenge and pose a serious 47 
health risk affecting both hospitalized patients and health care providers (1-3). β-48 
Lactamase-associated resistance is a predominant mechanism of resistance to β-lactam 49 
antibiotics in Enterobacteriaceae. The dissemination of resistance in these bacteria is 50 
frequently facilitated by transferring mobile genetic elements among bacteria (4). 51 
Currently, infections caused by multidrug-resistant (MDR) Gram-negative bacteria, in 52 
particular ESBL- producing Enterobacteriaceae, are among one of the most serious 53 
human health concerns (5). blaTEM, blaSHV, and blaCTX-M  genes are the most common 54 
ESBL genotypes among Enterobacteriaceae. ESBL-producing isolates characteristically 55 
hydrolyze cefotaxime, ceftazidime, cefepime and/or  monobactam aztreonam, rendering 56 
these antibiotics inactive (6-8). ESBLs are inhibited by β-lactamase inhibitors, namely 57 
clavulanate, sulbactam and tazobactam. False-negative ESBL test results using 58 
combination disc tests may result from high-level expression of AmpC β-lactamases, 59 
which masks the presence of ESBLs. Using CA and CX together allows detection of co-60 
production of ESBL and AmpC (9). In addition, AmpC β-lactamase (AmpC)-producers 61 
and co-producers of AmpC and ESBL have also been reported to be resistant to third-62 
generation cephalosporins, cephamycins or β-lactam/β-lactamase inhibitor combinations 63 
(10). Infections caused by AmpC- producing organisms are typically associated with 64 
resistance to multiple antibiotics, such as penicillins, oxyimino- 7-α-65 
methoxycephalosporins and monobactams (11, 12). In general, AmpC type enzymes are 66 
poorly inhibited by β-lactamase inhibitors, especially clavulanic acid. Phenotypic 67 
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AmpC confirmation tests are generally based on inhibition of AmpC by either 68 
cloxacillin or boronic acid derivatives. Boronic acid also inhibits class A 69 
carbapenemases (13), justifying the use of cloxacillin in the present study. Moreover, 70 
co-expression of ESBL and AmpC β-lactamases results in decreased susceptibility to 71 
aztreonam and β-lactam/lactamase inhibitors than those with either ESBL or AmpC β-72 
lactamase alone (14). This makes the selection of an effective antibiotic difficult for the 73 
treatment of infections caused by these recalcitrant bacteria.          74 
 A simple, rapid and inexpensive method for screening and discrimination between 75 
these enzymes at a phenotypic level could guide clinicians to prescribe an appropriate 76 
chemotherapy. The combined disc method has been used extensively because it is 77 
relatively easy to prepare and perform. However, this test requires at least 18 h or 78 
overnight to obtain the results. A resazurin reduction assay, a colorimetric method, is 79 
based upon the ability of active cells to reduce a blue colored resazurin to a pink colored 80 
resorufin (15). A colorimetric (resazurin containing) disc susceptibility method 81 
exhibited excellent reproducibility (16)  and high sensitivity and specificity in detection 82 
and differentiation of carbapenemase-producing Enterobacteriaceae (17). Cefpodoxime 83 
(CPD) is an attractive indicator cephalosporin for detection of ESBL production and 84 
may be used for screening according to EUCAST guidelines. There are several 85 
diagnostic methods that have been proposed for phenotypic confirmation of ESBL and 86 
AmpC β-lactamases, including the Etest, combined disc method e.g. MAST D68C test, 87 
double disc synergy test, automated broth microdilution test.  The time to result for 88 
these methods usually takes at least 18 h (9, 18, 19). Hence, the present study has 89 
investigated a resazurin chromogenic agar (RCA) method together with cefpodoxime 90 
(CPD) discs alone or  supplemented with clavulanic acid (CA), cloxacillin (CX), and 91 
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both CA and CX to screen for and discriminate between ESBL, AmpC, and co-92 
existence of ESBL-AmpC among Enterobacteriaceae.   93 
2. MATERIALS AND METHODS 94 
2.1  Bacterial isolates  95 
The present study employed a total of 86 β-lactamase-producing Enterobacteriaceae 96 
isolates to evaluate the performance of the RCA assay in rapid screening and 97 
discrimination of ESBL, AmpC, and co-producers of ESBL and AmpC. The organisms 98 
used in the present study are summarized in Table 1 (17, 20).  The molecular types 99 
included 15 Ambler class A ESBL producers (4 CTX-M-types, 3 SHV-types, 3 TEM-100 
types, 1 CTX-M+SHV-type, 3 SHV+TEM-types, and 1 CTX-M+SHV+TEM-type), 32 101 
Ambler class C AmpC producers (6 DHA family, 7 CIT family, 2 MOX family, 11 102 
EBC family, and 6 FOX family) and 9 co-producers of ESBL and AmpC (1 103 
TEM+ACT-type, 4 CTX-M+ACT-types, 1 TEM+SHV+ACT-type, 1 TEM+CTX-104 
M+ACT-type, 1 SHV+ACT type, and 1 SHV+CTX-M-ACT-type).  Thirty 105 
carbapenemase-producing isolates (8 KPC, 11 MBL, and 11 OXA-48 producers) were 106 
also included to validate the performance of the RCA plate assay.  A reference strain E. 107 
coli ATCC 25922 was used as a negative β-lactamase control strain. The following β-108 
lactamase-producing isolates obtained from the American Type Culture Collection 109 
(ATCC) and National Collection of Type Cultures (NCTC) were used as controls; E. 110 
cloacae ATCC BAA-1143 (blaACT-32), E. coli NCTC 13352 (blaTEM-10) and E. coli 111 
NCTC 13353 (blaCTX-M-15). 112 
 113 
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2.2 Resazurin chromogenic agar (RCA) plate and disc preparations 114 
RCA plates were prepared according to previous studies (16, 17). For the preparation 115 
of the antibiotic- or β-lactamase inhibitor-containing discs, 10 µg of CPD discs (MAST 116 
Group, UK) were supplemented with 10 µl of 1 mg/mL CA (Sigma-Aldrich, UK), 10 µl 117 
of CX (Sigma-Aldrich, UK) at a concentration of 50 mg/mL, or impregnated with both 118 
CA and CX. Meropenem (MER) discs (10 µg) were prepared by adding 10 µl of MER 119 
(Sigma-Aldrich, UK) at a concentration of 1 mg/mL to blank discs (6.5 mm diameter, 120 
MAST Group, UK). Prior to performing disc diffusion susceptibility testing, the discs 121 
were air-dried in a  biosafety cabinet for 1 h.  122 
2.3 Disc diffusion susceptibility testing 123 
The algorithm for phenotypic screening of ESBL, AmpC, and co-producers of ESBL 124 
and AmpC is illustrated in Figure 1.  The experimental procedure for disc diffusion 125 
susceptibility testing was carried out according to the Clinical Laboratory Standards 126 
Institute (CLSI) guidelines (21). Briefly, a sterile swab soaked in a 0.5 McFarland 127 
standard of test organism was spread entirely on the surface of the RCA plate.  Discs 128 
containing CPD alone, CPD plus CA, CPD plus CX, CPD plus CA and CX, and MER 129 
alone were placed equidistantly on the RCA’s surface. The MER disc was used to 130 
screen for carbapenem resistance including carbapenemase production. The inhibition 131 
zone diameters were scrupulously measured and interpreted following incubation at 37 132 
°C for 7 h by observing a change in the medium from the original blue (resazurin) 133 
colour  to pink (resorufin).  The interpretation criteria in screening and differentiation of 134 
ESBL, AmpC, and co-β-lactamases were based upon a previous report as presented in 135 
Table 2 (19). An increase in zone diameter (≥5 mm) of CPD supplemented with β-136 
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lactamase inhibitor compared with CPD alone was considered as synergistic activity. To 137 
interpret the results, CA synergy was considered as a positive result for ESBL, while 138 
CX synergy and CA plus CX synergy were noted as positive results for AmpC and co-139 
production of ESBL and AmpC, respectively. A zone diameter of MER < 25 mm was 140 
used at a cut-off point to screen for the presence of carbapenemases. Sensitivity and 141 
specificity of the RCA assay with a combined disc method were calculated by 142 
comparing the results with molecular types from PCR and sequencing data. A box-and-143 
whisker plot was analyzed using SPSS statistical analysis program version 18 (SPSS 144 
Inc, USA) to elucidate the distribution of zone diameters of discs against different β-145 
lactamase producers.   146 
3.  RESULTS 147 
Using the RCA assay along with a combined disc method for phenotypic confirmation 148 
of ESBL, AmpC, and co-expression of ESBL plus AmpC clearly showed the inhibition 149 
zone diameters within 7 h (Figure 2).  Figure 3 illustrates the distribution of the zone 150 
diameters of CPD impregnated with and without CA, CX, or CA plus CX, and MER 151 
alone against ESBL, AmpC, co-existence of ESBL and AmpC, and carbapenemase-152 
producing Enterobacteriaceae. For screening of ESBL-producing isolates, the median 153 
zone diameter of CPD alone was 6.5 mm (range = 6.5-16 mm) and diameters of CPD 154 
supplemented with CA, CX, or CA plus CX were 22 mm (range = 19-25 mm), 6.5 mm 155 
(range = 6.5-17 mm), and 23 mm (range = 21-25 mm), respectively.  MER discs 156 
exhibited potential activity in inhibition of ESBL producers with a median zone 157 
diameter 25 mm (range = 23-27 mm) (Figure 3A). A substantial increase in zone 158 
diameters of CA-containing discs compared with the discs without CA was only 159 
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observed in ESBL-producing isolates.  The mean zone increase of CPD plus CA 160 
compared with CPD alone was 14.60 mm (range = 5-17.50 mm). No marked increase in 161 
zone diameter was observed in AmpC producers (mean = 0.48 mm and range = 1.5-3.5 162 
mm), co-producers of ESBL and AmpC (mean = 2.72 mm and range 1.5-8.5 mm), as 163 
well as carbapenemase-producing isolates (mean = 0.37 mm and range = 0-5.5 mm).  164 
The RCA assay with combined disc method successfully detected all test ESBL 165 
producers with 100% sensitivity and 98.6 % specificity (Table 2). A false-positive result 166 
was observed in an OXA-48-producing E. coli.             167 
In AmpC producers, an increase in median zone diameters was seen in CX-containing 168 
discs. CPD plus CX and CPD plus CX plus CA had equally a median zone diameter of 169 
20 mm and a range 12-26 mm. The median zone diameter of CPD against these isolates 170 
was 7.25 mm (range = 6.5-20 mm) which was similar to CPD plus CA (median = 8 mm 171 
and range =6.25-21 mm). MER discs inhibited the growth of AmpC-producing isolates 172 
at a median zone diameter of 25 mm and range 23-28mm (Figure 3B).  The mean 173 
difference of zone diameter of CPD plus CX versus CPD alone was 10.09 mm (range = 174 
5.50 -16.50 mm) against AmpC producers, whilst no dramatic difference in mean zone 175 
increase was observed in ESBL producers (mean =0.33 mm and range = 0-2 mm), co-176 
producers of ESBL and AmpC (mean = 4.33 mm and range = 1-7.5 mm), or 177 
carbapenemase producers (mean = 0.88 mm and range = 0-9.5 mm). The RCA assay 178 
demonstrated an excellence performance in the screening of AmpC-producing strains by 179 
detecting all test AmpC producers (100 % sensitivity), but there were two false-180 
positives in KPC-3-producing K. pnuemoniae and OXA-48-producing E. coli (96.36 % 181 
specificity; Table 2).               182 
For screening of ESBL and AmpC-co-producing Enterobacteriaceae, CPD discs alone 183 
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exhibited a median zone diameter of 9 mm (range = 6.5-22 mm). CPD plus CA (median 184 
= 15 mm and range = 6.5-22 mm) and CPD plus CX (median = 14 mm and range = 10-185 
27 mm) showed a slight increase in median zone diameter compared with CPD alone. 186 
CPD plus CA plus CX demonstrated excellent activity in inhibiting the growth of ESBL 187 
and AmpC co-producers. The median zone was significantly increased (median = 24 188 
mm and range = 21-27 mm) in comparison with those of CPD alone, CPD plus CA, and 189 
CPD plus CX. The median zone diameter and zone range of MER against these isolates 190 
were 25 mm and 23-26 mm, respectively (Figure 3C). The mean difference in zone 191 
diameter of CPD plus CA and CX versus CPD plus CA, or versus CPD plus CX was 192 
also calculated. The mean zone increase of CPD plus CA and CX versus CPD plus CA 193 
was 11. 61 mm (range=5-19.5 mm). A similar result was observed in CPD plus CA and 194 
CX versus CPD plus CX. The sensitivity and specificity of the RCA assay with the 195 
combined disc method were 88.89% and 100%, respectively (Table 2). The assay failed 196 
to detect ESBL activity in a SHV plus ACT-producing E. aerogenes. Furthermore, in 197 
carbapenemase-producing isolates, the median zone diameters of CPD with and without 198 
CA, CX, or CA and CX were not markedly different, while the ranges did vary. The 199 
MER disc alone had a median zone diameter of 17 mm and range 6.5-25 mm. A 200 
reference strain E. coli ATCC 25922 was inhibited by a CPD disc alone with zone 201 
diameter 25 mm which was in the susceptible range according to the CLSI breakpoint 202 
(≥21 mm) (22). The findings of this study demonstrated that the RCA assay with CPD 203 
combination discs showed an excellent performance in screening of and differentiation 204 
between ESBL, AmpC, and co-production of ESBL and AmpC in Enterobacteriaceae.  205 
 206 
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4. DISCUSSION 207 
Resistance to β-lactams, the most potent bactericidal antibiotics commonly used for the 208 
treatment of bacterial infections, has been continuously documented throughout the 209 
globe. β-Lactamase-mediated resistance is a major mechanism that can potentially 210 
render β-lactams inactive by hydrolytically cleaving the amide bond of the β-lactam 211 
ring (23). To guide clinicians to prescribe antibiotic therapy appropriately, development 212 
of quick  phenotypic methods is necessary. The detection of the presence of β-lactamase 213 
enzymes in Gram-negative bacteria at the phenotypic level is useful because it is not 214 
costly compared with genotypic tests (PCR and sequencing). Also, a phenotypic method 215 
does not require skilled and experienced technicians (24). The principle of the 216 
phenotypic test is fundamentally based upon a synergistic effect between antibiotics and 217 
β-lactamase inhibitors (25). Several phenotypic tests for the detection of β-lactamase 218 
enzymes in Gram-negative bacteria have currently been proposed including disc 219 
diffusion assays and broth microdilution methods (9, 19, 26, 27). The time to interpret 220 
these results usually takes 18 h or overnight incubation (28, 29).  In the present study, 221 
we propose the rapid screening method using RCA assay along with CPD combined 222 
disc method to detect  the presence of and discriminate between β-lactamases within 7 223 
h.                                                                                                                                  224 
CA synergy test using the RCA assay with CPD combined discs to confirm the presence 225 
of ESBL production in Enterobacteriaceae was capable of detecting all test ESBL-226 
producing isolates. There was only one false-positive found in an OXA-48-producing 227 
isolate. This finding agrees with a previous report published by Derbyshire and 228 
colleagues (26). They found that a CA synergy test using CPD was able to detect all 117 229 
ESBL producers indicated by a ≥ 5 mm increase in zone diameter of CPD plus CA in 230 
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comparison with CPD alone. This synergy test could not detect ESBLs in the co-231 
presence with AmpCs. Similarly, CPD exhibited excellent performance in the screening 232 
of ESBL in K. pneumoniae and E. coli, but poor sensitivity for K. oxytoca (30, 31).  The 233 
presence of ESBLs may also be masked by carbapenemases such as MBLs or KPCs 234 
(32). Furthermore, not all OXA-48-variants exhibit significant carbapenemase activity, 235 
some OXA-48 variants such as OXA-163 and OXA-405 have been reported to be 236 
resistant to either carbapenem antibiotics or to extended-spectrum cephalosporins. 237 
These two variants were significantly inhibited by CA (33, 34). We speculate that a 238 
OXA-48-like-producing isolate used in the present study might have low 239 
carbapenemase activity as indicated by relatively large zone diameter for MER (22 mm) 240 
and might also co-produce ESBL.                                                                         241 
For screening of AmpC-producing isolates using CX synergy test, the assay was able to 242 
detect all AmpC producers and two-false positive results (100% Sensitivity and 96.36% 243 
specificity). This result is consistent with many previous works reporting a good 244 
performance of CPD and CX synergy test in detection of these enzymes. In one such 245 
study MAST
®
 D68C successfully detected almost all AmpC producers whilst a few 246 
false-positive results were also reported (96.7 % sensitivity and 96.9% specificity). The 247 
test could not detect the low production of AmpC β-lactamases in AmpC-producing 248 
isolates (19).  A similar result was reported by Ingram and colleagues, they found that 249 
MAST
®
 D68C exhibited a sensitivity and specificity above 90% in detection of the 250 
presence of AmpC β-lactamase in Enterobacteriaceae. In agreement with a previous 251 
study, MAST-4 disc demonstrated good sensitivity (92%) and specificity (86.7%) in the 252 
detection of AmpC-producing nosocomial Klebsiella isolates (35). Combined activity of 253 
ESBL and AmpC in the same strain can result in phenotypic detection failure (36).  Co-254 
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production with AmpC β-lactamases can mask ESBL production with CLSI 255 
confirmatory tests leading to false-negative results (37). Therefore, adding two or more 256 
specific β-lactamase inhibitors could exclude different types of β-lactamase in the same 257 
strain. In the present study, we used CA plus CX synergy test to discriminate co-258 
producers of ESBL and AmpC.  The assay was able to detect 8 co-producers of ESBL 259 
and AmpC. Only AmpC was detected in one co-producer of ESBL and AmpC. This 260 
false-negative isolate was susceptible to CPD according to the CLSI breakpoint 261 
(Clinical Laboratory Standards Institute, 2014). The finding from this study is similar to 262 
the result from a previously mentioned study where MAST
®
 D68C was reported to 263 
successfully detect all 8 ESBL and AmpC-co-producing isolates (19).         264 
To screen carbapenemase-producing isolates, it has been recommended to use a cut-off 265 
point lower than 25 mm for MER disc because the zone diameter of MER in some 266 
OXA-48 like-producing bacteria is still in the susceptible range (≥ 23 mm) (38, 39). The 267 
current study found that MER zone diameters against ESBL, AmpC, and Co-ESBL and 268 
AmpC ranged from 23-28 mm, whilst in carbapenemase-producing isolates zone 269 
diameters ranged from 6.5 – 25 mm. Only one OXA-48 producing isolate had a zone 270 
diameter of 25 mm. Thus, the isolates showing zone diameters < 25mm for 10 µg MER 271 
disc should be further investigated to detect the distinct type of carbapenemase (metallo-272 
β-lactamases, Klebsiella pneumoniae carbapenemases, and OXA-48 like 273 
carbapenemases) or AmpC plus porin loss.                           274 
To summarize, the combined disc test is commonly used in many microbiological 275 
laboratories, because it is very simple.  The conventional method takes at least 18 h to 276 
observe the inhibition zone diameter. In the present study, we support the use of the 277 
RCA assay to improve a time to result for the disc diffusion susceptibility test.  The 278 
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result from RCA assay can be observed within 7 h.  It also demonstrates excellent 279 
sensitivity and specificity for differentiation of ESBL, AmpC, and co-ESBL and AmpC-280 
producing Enterobacteriaceae. The RCA assay could be applicable to commercially 281 
available discs, including MAST discs (Mast Group, UK) and it can also be applied in 282 
CLSI ESBL confirmatory tests and any disc diffusion method. However, a larger 283 
sample size of clinical isolates is still required to further validate and establish the 284 
robustness of this assay. A rapid phenotypic method that can detect and differentiate the 285 
different types of β-lactamase would improve the effectiveness of antibiotic 286 
administration and would also help to control the dissemination of the infection caused 287 
by these refractory bacteria.   288 
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FIGURE LEGENDS  439 
Figure 1.  The algorithm for confirmation of and differentiation between  ESBL, 440 
AmpC, and co-production of ESBL and AmpC in Enterobacteriaceae.   CA= clavulanic 441 
acid (10 µg); CX = cloxacillin (500 µg). 442 
Figure  2.  Phenotypic results from RCA plate assay with a combined disc method at 7 443 
h.  A = cefpodoxime (10 µg); B = cefpodoxime (10 µg) + clavulanic acid (10 µg); C 444 
=cefpodoxime (10 µg) + cloxacillin (500 µg); D= cefpodoxime (10 µg) + clavulanic 445 
acid (10 µg) + cloxacillin (500 µg);E = meropenem (10 µg).  446 
Figure 3.  Distribution of zone diameters of cefpodoxime (CPD) alone,   CPD with 447 
clavulanic acid, CPD with cloxacillin, CPD with both clavulanic acid and cloxacillin 448 
and meropenem alone.   A = ESBL producers (n=15); B = AmpC producers (n=32); C= 449 
co-producers AmpC and ESBL (n=9); D = carbapenemase producers (n=30). 450 
CPD=cefpodoxime (10 µg); CA= clavulanic acid (10 µg); CX=cloxacillin (500 µg); 451 
MER = meropenem (10 µg). º = mild outlier; * extreme outlier.   452 
 453 
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Tables 454 
 455 
Table 1. Summary of  ESBL, AmpC, ESBL+AmpC and carbapenemase-producing 456 
isolates used in the present study. Abbreviation for Organism; EC = E. coli, KP = K. 457 
pneumoniae, EA= E. aerogenes, ECL = E. cloacae, MM= M. morganii, CF=C. freundii, 458 
KOX= K. oxytoca, KOZ= K. ozaenae.  Abbreviation for β-lactamase; ESBL=extended-459 
spectrum-β-lactamase, KPC= Klebsiella pneumoniae carbapenemase, MBL = metallo-460 
β-lactamase 461 
Table 2  Interpretation criteria, sensitivity, and specificity of a combined disc synergy 462 
method along with RCA assay for rapid screening of ESBL, AmpC, and co-producers 463 
of ESBL and AmpC among Enterobacteriaceae. CPD=cefpodoxime (10 µg); CA= 464 
clavulanic acid (10 µg); CX=cloxacillin (500 µg) 465 
 466 
 467 
 468 
 469 
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Table 1. Summary of ESBL, AmpC, ESBL+AmpC and carbapenemase-producing isolates 
used in the present study.  
Group of β-lactamases EC KP EA ECL MM CF KOX KOZ 
Ambler class A  ESBL (n =15) 
   CTX-M family (n=4) 4 - - - - - -  
   SHV family  (n=3) - 2 - 1 - - - - 
   TEMfamily  (n=3) 3 - - - - - - - 
   CTX-M + SHV (n=1) - 1 - - - - - - 
   SHV + TEM  (n=3) - 3 - - - - - - 
  CTX-M + SHV+TEM (n=1) - 1 - - - - - - 
Ambler class C  AmpC (n =32) 
    DHA family (n=6) 2 2 - - 2 - - - 
    CIT   family  (n= 7) 4 1 1 - - 1 - - 
    MOX  family (n=2) 1 - - - - 1 - - 
    EBC   family (n=11) 1 1 3 6 - - - - 
    FOX  family (n=6) 2 - 3 1 - - - - 
Class A + Class C   (n=9) 
    TEM+ACT (n=1) - - - 1 - - - - 
    CTX-M + ACT (n=4) 1 - 1 - - 2 - - 
    TEM+SHV+ACT (n=1) - - 1 - - - - - 
    TEM+CTX-M+ACT (n=1) - - 1 - - - - - 
    SHV+ACT  (n=1) - - 1 - - - - - 
    SHV+CTX-M+ACT (n=1) - - 1 - - - - - 
Carbapenemase producers (n=30) 
  class A KPC (n=8) 2 5 - - - - 1 - 
  class A MBL (n=11) 1 7 - 2 - - - 1 
 Ambler class D OXA-48 (n=11) 4 5 - 2 - - - - 
Total (number of isolates) 25  28 12 13 2 4 1 1 
 
 
Abbreviation for Organism; EC = E. coli, KP = K. pnuemoniae, EA= E. aerogenes, 
ECL = E. cloacae, MM = M. morganii, CF = C. freundii, KOX = K. oxytoca, KOZ = 
K. ozaenae. Abbreviation for β-lactamase; ESBL = extended-spectrum-β-lactamase, 
KPC = Klebsiella pneumoniae carbapenemase, MBL = metallo-β-lactamase. 
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Table 2. Interpretation criteria, sensitivity, and specificity of a combined disc synergy 
method along with RCA assay for rapid screening of ESBL, AmpC, and co-producers of 
ESBL and AmpC among Enterobacteriaceae. 
Synergy test Definition of the  test ESBL AmpC ESBL+ 
AmpC 
Sensitivity Specificity 
CA synergy test CPD+CA vs CPD ≥ 5 mm  and 
CPD+CA+CX vs CPD+CX ≥ 5 mm 
+ - - 100 
(15/15) 
98.6 
(71/72) 
CX synergy test CPD+CX vs CPD ≥ 5 mm  and 
CPD+CA+CX vs CPD+CA ≥ 5mm 
- + - 100 
(32/32) 
96.36 
(53/55) 
CA+CX synergy test Both CPD+CA+CX vs CPD+CX    
≥ 5 mm and CPD+CA+CX vs 
CPD+CA ≥ 5 mm 
- - + 88.89 
(8/9) 
100 
(78/78) 
CPD=cefpodoxime (10 µg); CA= clavulanic acid (10 µg); CX=cloxacillin (500 µg) 
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Figure 1.  The algorithm for confirmation of and differentiation between  ESBL, AmpC, and co-production of 
ESBL and AmpC in Enterobacteriaceae.   CA= clavulanic acid (10 µg); CX = cloxacillin (500 µg).  
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Figure  2.  Phenotypic results from RCA plate assay with a combined disc method at 7 h.  A = cefpodoxime 
(10 µg); B = cefpodoxime (10 µg) + clavulanic acid (10 µg); C =cefpodoxime (10 µg) + cloxacillin (500 
µg); D= cefpodoxime (10 µg) + clavulanic acid (10 µg) + cloxacillin (500 µg);E = meropenem (10 µg).  
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Figure 3.  Distribution of zone diameters of cefpodoxime (CPD) alone,   CPD with clavulanic acid, CPD with 
cloxacillin, CPD with both clavulanic acid and cloxacillin and meropenem alone.   A = ESBL producers 
(n=15); B = AmpC producers (n=32); C= co-producers AmpC and ESBL (n=9); D = carbapenemase 
producers (n=30). CPD=cefpodoxime (10 µg); CA= clavulanic acid (10 µg); CX=cloxacillin (500 µg); MER = 
meropenem (10 µg). º = mild outlier; * extreme outlier.    
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